SEHK:2142Biotechs
HBM Holdings (SEHK:2142) Stock Valuation After New IND Milestone For Cancer Antibody HBM7004
HBM Holdings (SEHK:2142) is back in focus after China’s National Medical Products Administration accepted its investigational new drug filing for HBM7004, a bispecific antibody for advanced solid tumors, following earlier U.S. FDA clearance.
See our latest analysis for HBM Holdings.
Despite the positive regulatory news, the stock’s recent momentum has cooled, with a 30 day share price return down 21.58% and the year to date share price return down 16.97%. This comes even as the 1 year total...